Home | Contact Us | FAQ | Search & Site Map | Link to Us
Sign In | Join | Other 45 Sites in Network
Home
Discussion Groups
General
GeneralCardiologyVisionDentistryPharmacyLaboratoryNutritionAlternative
Diseases and Disorders
AIDSAlzheimer'sArthritisAsthmaCancerBreast CancerDiabetesEpilepsyGlaucomaHepatitisHerpesLupusProstate BPHProstate CancerProstatitisSinusitisTinnitus

Medical Forum / Diseases and Disorders / Prostate Cancer / August 2005

Tip: Looking for answers? Try searching our database.

Calcium fights prostate cancer

Thread view: 
Enable EMail Alerts  Start New Thread
Thread rating: 
c palmer - 15 Aug 2005 20:11 GMT
Monday, 15-Aug-2005 

 Calcium, more familiar in its role as one of the building blocks of
the body, is being enlisted as a tool in the fight against prostate
cancer.
Researchers in Flinders University's Department of Medical Biochemistry
are investigating a pharmacological approach that will use calcium ions
within cancerous cells in the prostate to kill those cells.
"There are a series of what we call calcium channels in the surface of
the prostate cancer cells, which effectively regulate the level of
calcium within the cells," Professor Greg Barritt said.
His research team is working to develop a procedure that will
overactivate the channels, thereby producing levels of calcium that are
toxic to the cancer cells.
Professor Barritt said that in an ageing population that increasingly
survives other diseases, prostate cancer is emerging as a major cause of
death for men.
Along with surgical removal of the prostate, he said hormone ablation,
the treatment that removes the androgen hormones - chiefly testosterone
- on which the cancer is dependent, acts as a good first-line defence.
"In most patients, the cancer will regress after this treatment,
particularly if the cancer is caught early," he said.
In some patients, however, disease reoccurs as remnant cancer cells
mutate to become hormone independent.
"At the moment there are limits to what we can do in terms of treatment
for some people with hormone refractory prostate cancer," Professor
Barritt said.
"Our research is directed towards a treatment for that form of prostate
cancer, and it may well be used in conjunction with other treatments
such as chemotherapy."
According to Professor Barritt, the new strategy effectively mimics
calcium's role in cell degradation which occurs naturally, for example,
in the degradation of nerve cells in the body.
Professor Barritt said the public tends to think of calcium in a
beneficial role, particularly in regard to the structure of bones and
the crucial role of Vitamin D in the diet.
And indeed calcium, in its intracellular form, is vital throughout the
body - it is present in most cells of the body including the nerves and
skin, and the contraction of heart and skeletal muscles is dependent on
intracellular calcium.
Yet calcium can also play a more destructive role: "One of the functions
of calcium - a normal one in most instances - is to help cells to die,"
Professor Barritt said.
When new nerve pathways are developed, for instance, the old ones become
redundant, and calcium acts as the terminating agent.
"We are basically activating the same pathway when we are trying to kill
the cancer cells," Professor Barritt said.
He said that there are still challenges to overcome before the approach
can take its place among the battery of treatments used to combat cancer
of the prostate.
One of the problems is accurate targeting of the prostate. While
incidentally killing the normal cells of the prostate gland along with
the cancerous cells does not appear to be a problem - surgical treatment
of cancer involves wholesale removal of the prostate in any case - it is
still necessary to confine the effects of the treatment.
"One of the methods we are using to achieve that specificity is, in
part, a gene targeting method. In principle, we are using what we call
promoters of protein expression specific to the prostate cells, which
switch on protein synthesis in prostate cells but not in other cells."
There is also a second, chemical method that uses the cancer itself,
relying on proteins produced only by prostate cancer cells to achieve
accurate targeting.
Professor Barritt said that prostate cancer begins with a phase known as
benign hyperplasia, when genetic or environmental factors trigger the
prostate cells into growing larger and multiplying.
If unchecked, the cells may become carcinogenic and invasive, affecting
tissue around the prostate and travelling in the blood to other sites in
the body, favouring the bones and particularly the nearby spine.
"This is the invasive, metastatic stage, and we really need to be
developing a treatment that targets those cells as well as the ones in
the prostate, which makes the challenge of targeting even more
complicated," Professor Barritt said.
The calcium channels have emerged in yet another possible role, this
time as an aid to diagnosis and prognosis in prostate cancer.
Professor Barritt said that as prostate enlargement progresses to its
more aggressive stage, the cancerous cells display a higher expression
of the calcium channel.
"If you are able to measure the amount of the channel that is present,
it might be a useful predictor of the cells' future behaviour," he said.
"In patients who have had the prostate removed and have undergone
hormone ablation therapy, you may be able to predict whether that person
is going to go into a strongly metastasising and invading tumour, and
then apply some appropriate treatments at an early stage, rather than
waiting for it to happen."
http://www.flinders.edu.au
 

knowledge is power - growing old is mandatory - growing wise is optional    
"Many more men die with prostate cancer than of it. Growing old is
invariably fatal. Prostate cancer is only sometimes so."
http://community.webtv.net/PALMER_ENT/doc
Lorelei - 20 Aug 2005 02:04 GMT
Monday, 15-Aug-2005

Calcium, more familiar in its role as one of the building blocks of
the body, is being enlisted as a tool in the fight against prostate
cancer.
Researchers in Flinders University's Department of Medical Biochemistry
are investigating a pharmacological approach that will use calcium ions
within cancerous cells in the prostate to kill those cells.
"There are a series of what we call calcium channels in the surface of
the prostate cancer cells, which effectively regulate the level of
calcium within the cells," Professor Greg Barritt said.
His research team is working to develop a procedure that will
overactivate the channels, thereby producing levels of calcium that are
toxic to the cancer cells.
Professor Barritt said that in an ageing population that increasingly
survives other diseases, prostate cancer is emerging as a major cause of
death for men.
Along with surgical removal of the prostate, he said hormone ablation,
the treatment that removes the androgen hormones - chiefly testosterone
- on which the cancer is dependent, acts as a good first-line defence.
"In most patients, the cancer will regress after this treatment,
particularly if the cancer is caught early," he said.
In some patients, however, disease reoccurs as remnant cancer cells
mutate to become hormone independent.
"At the moment there are limits to what we can do in terms of treatment
for some people with hormone refractory prostate cancer," Professor
Barritt said.
"Our research is directed towards a treatment for that form of prostate
cancer, and it may well be used in conjunction with other treatments
such as chemotherapy."
According to Professor Barritt, the new strategy effectively mimics
calcium's role in cell degradation which occurs naturally, for example,
in the degradation of nerve cells in the body.
Professor Barritt said the public tends to think of calcium in a
beneficial role, particularly in regard to the structure of bones and
the crucial role of Vitamin D in the diet.
And indeed calcium, in its intracellular form, is vital throughout the
body - it is present in most cells of the body including the nerves and
skin, and the contraction of heart and skeletal muscles is dependent on
intracellular calcium.
Yet calcium can also play a more destructive role: "One of the functions
of calcium - a normal one in most instances - is to help cells to die,"
Professor Barritt said.
When new nerve pathways are developed, for instance, the old ones become
redundant, and calcium acts as the terminating agent.
"We are basically activating the same pathway when we are trying to kill
the cancer cells," Professor Barritt said.
He said that there are still challenges to overcome before the approach
can take its place among the battery of treatments used to combat cancer
of the prostate.
One of the problems is accurate targeting of the prostate. While
incidentally killing the normal cells of the prostate gland along with
the cancerous cells does not appear to be a problem - surgical treatment
of cancer involves wholesale removal of the prostate in any case - it is
still necessary to confine the effects of the treatment.
"One of the methods we are using to achieve that specificity is, in
part, a gene targeting method. In principle, we are using what we call
promoters of protein expression specific to the prostate cells, which
switch on protein synthesis in prostate cells but not in other cells."
There is also a second, chemical method that uses the cancer itself,
relying on proteins produced only by prostate cancer cells to achieve
accurate targeting.
Professor Barritt said that prostate cancer begins with a phase known as
benign hyperplasia, when genetic or environmental factors trigger the
prostate cells into growing larger and multiplying.
If unchecked, the cells may become carcinogenic and invasive, affecting
tissue around the prostate and travelling in the blood to other sites in
the body, favouring the bones and particularly the nearby spine.
"This is the invasive, metastatic stage, and we really need to be
developing a treatment that targets those cells as well as the ones in
the prostate, which makes the challenge of targeting even more
complicated," Professor Barritt said.
The calcium channels have emerged in yet another possible role, this
time as an aid to diagnosis and prognosis in prostate cancer.
Professor Barritt said that as prostate enlargement progresses to its
more aggressive stage, the cancerous cells display a higher expression
of the calcium channel.
"If you are able to measure the amount of the channel that is present,
it might be a useful predictor of the cells' future behaviour," he said.
"In patients who have had the prostate removed and have undergone
hormone ablation therapy, you may be able to predict whether that person
is going to go into a strongly metastasising and invading tumour, and
then apply some appropriate treatments at an early stage, rather than
waiting for it to happen."
http://www.flinders.edu.au

knowledge is power - growing old is mandatory - growing wise is optional
"Many more men die with prostate cancer than of it. Growing old is
invariably fatal. Prostate cancer is only sometimes so."
http://community.webtv.net/PALMER_ENT/doc

Curt's onc came back from a symposium with news of high doses of calcium for
Pca. the problem is that nobody has made a concentrated pill yet so curt was
going to have to take ****75**** tablets one day per week. you can imagine
how that went over with Mr. Compliance.

I have a bottle here. it is Calcitrol 0.5 mcg capsules. the label says take
25 capsules by mouth (whew) three times daily every 7 days.
Doc Bloom says that a new pill will be coming soon so it won't take so many
pills to reach therapeutic dosage.
Lori
 
Sign In
Join
My Latest Posts
My Monitored Threads
My Blog
My Photo Gallery
My Profile
My Homepage

Start New Thread
Enable EMail Alerts
Rate this Thread



©2008 Advenet LLC   Privacy Policy - Terms of Use
This website includes both content owned or controlled by Advenet as well as content owned or controlled by third parties.